Maintenance treatment study for AML in remission
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older with AML that is in first remission (either complete remission or remission with incomplete blood recovery).
- You are not a good candidate for an immediate allogeneic stem cell transplant (a transplant using donated cells).
- You must have received chemotherapy to get into remission (either intensive chemotherapy, or lower-intensity treatments for multiple cycles, depending on the group).
- You must have some space in key lab and organ function numbers: bilirubin ≤ 1.5 times normal, creatinine ≤ 2.5 times normal, ANC > 0.5, and platelets ≥ 50.
- You should be well enough to do daily activities: ECOG performance status 0 to 3.
- If you can become pregnant or have a partner who can, you must agree to reliable birth control (or abstinence) during the study and for 30 days after stopping.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This trial tests a maintenance treatment called 'ITIVA' for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy and consolidation therapy. The goal is to see if this treatment helps keep the leukemia from coming back.
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
This trial tests a combination of drugs for people with AML who, after initial treatment, have very low levels of leukemia still present (called measurable residual disease or MRD). The goal is to wipe out these remaining cells and reduce the chance of the cancer coming back.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your blood cancer from coming back. It is for people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or MDS/AML who have had or will have a stem cell transplant.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.